Krystal Biotech Business Summary

Krystal Biotech, Inc. (KRYS) is a commercial-stage biotechnology leader that generates revenue primarily through the global sale of VYJUVEK, the first-ever redosable, topically applied gene therapy for Dystrophic Epidermolysis Bullosa (DEB). The company operates through a single business segment focused on the development and commercialization of genetic medicines using its proprietary Skin TARgeted Delivery (STAR-D) platform, which utilizes an engineered HSV-1 vector to deliver functional genes directly to skin, lung, and ophthalmic tissues. As of early 2026, the company has achieved significant market penetration in the U.S., Europe, and Japan, with preliminary 2025 annual revenues reaching approximately $389 million. Krystal Biotech competes directly with Abeona Therapeutics, Sarepta Therapeutics, and Moderna, distinguishing itself as a market leader through its non-invasive, redosable delivery mechanism that avoids the immunogenicity and surgical requirements common in traditional AAV-based or cell-graft therapies. The company was founded by the husband-and-wife team of Krish S. Krishnan, who serves as Chairman and CEO, and Suma Krishnan, the President of Research & Development. Both founders possess a high-pedigree background in the pharmaceutical industry, having previously held senior leadership roles at New River Pharmaceuticals (where they were instrumental in the development and $2.6 billion sale of the blockbuster drug Vyvanse) and Intrexon Corporation. The executive team is supported by key leaders including Kathryn Romano (EVP & Chief Accounting Officer) and David Chien (SVP, Clinical Development). Krystal’s governance is bolstered by a board of directors featuring industry veterans such as Julian Gangolli, former President of North America at Greenwich Biosciences, and Dan Janney of Alta Partners. Notable institutional backing includes Frazier Healthcare Partners and Sun Pharma, reflecting strong investor confidence in the company's expanding pipeline of inhaled and ophthalmic gene therapies.